Ikena Oncology Valuation
| IKNA Stock | USD 1.32 0.02 1.54% |
Today, the firm appears to be overvalued. Ikena Oncology retains a regular Real Value of $1.17 per share. The prevalent price of the firm is $1.32. Our model calculates the value of Ikena Oncology from evaluating the firm fundamentals such as Return On Asset of -0.2, shares owned by insiders of 4.54 %, and Return On Equity of -0.33 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Ikena Oncology's price fluctuation is very risky at this time. Calculation of the real value of Ikena Oncology is based on 3 months time horizon. Increasing Ikena Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Ikena Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ikena Stock. However, Ikena Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.32 | Real 1.17 | Hype 1.3 | Naive 1.3 |
The real value of Ikena Stock, also known as its intrinsic value, is the underlying worth of Ikena Oncology Company, which is reflected in its stock price. It is based on Ikena Oncology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ikena Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ikena Oncology helps investors to forecast how Ikena stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ikena Oncology more accurately as focusing exclusively on Ikena Oncology's fundamentals will not take into account other important factors: Ikena Oncology Total Value Analysis
Ikena Oncology is currently estimated to have valuation of (53.16 M) with market capitalization of 61.77 M, debt of 7.52 M, and cash on hands of 192.81 M. The negative valuation of Ikena Oncology may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Ikena Oncology fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(53.16 M) | 61.77 M | 7.52 M | 192.81 M |
Ikena Oncology Asset Utilization
One of the ways to look at asset utilization of Ikena is to check how much profit was generated for every dollar of assets it reports. Ikena Oncology retains a negative application of resources of -0.2 (percent), losing $0.002044 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Ikena Oncology shows how discouraging it operates for each dollar spent on its resources.Ikena Oncology Ownership Allocation
Ikena Oncology has a total of 48.26 Million outstanding shares. The majority of Ikena Oncology outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ikena Oncology to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ikena Oncology. Please pay attention to any change in the institutional holdings of Ikena Oncology as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Ikena Oncology Profitability Analysis
Net Loss for the year was (49.23 M) with loss before overhead, payroll, taxes, and interest of (30.88 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ikena Oncology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ikena Oncology and how it compares across the competition.
About Ikena Oncology Valuation
The stock valuation mechanism determines Ikena Oncology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Ikena Oncology. We calculate exposure to Ikena Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ikena Oncology's related companies.Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Ikena Oncology Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 48.3 M |
Complementary Tools for Ikena Stock analysis
When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |